Market closed

Monte Rosa Therapeutics/$GLUE

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Monte Rosa Therapeutics

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Ticker

$GLUE
Trading on

Industry

Biotechnology

Employees

133

GLUE Metrics

BasicAdvanced
$426M
Market cap
-
P/E ratio
-$1.77
EPS
1.30
Beta
-
Dividend rate
$426M
1.3
$10.11
$3.21
1.4M
6.033
5.83
19.494
21.269
-28.43%
-61.23%
31.296
2.07
2.07
-7.464
-34.40%
-29.85%

What the Analysts think about GLUE

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.

GLUE Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

GLUE Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GLUE

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Monte Rosa Therapeutics stock?

Monte Rosa Therapeutics (GLUE) has a market cap of $426M as of December 22, 2024.

What is the P/E ratio for Monte Rosa Therapeutics stock?

The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of December 22, 2024.

Does Monte Rosa Therapeutics stock pay dividends?

No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of December 22, 2024.

When is the next Monte Rosa Therapeutics dividend payment date?

Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Monte Rosa Therapeutics?

Monte Rosa Therapeutics (GLUE) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.